OGIVRI (Alphapharm Pty Ltd)

OGIVRI (powder for injection) is indicated for the treatment of:

• HER2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy
• HER2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant OGIVRI
• patients with metastatic breast cancer who have tumours that overexpress HER2:
  1. as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;
  2. in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or,
  3. in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer

OGIVRI is also indicated, in combination with cisplatin and either capecitabine or 5-FU, for the treatment of patients with HER2 positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.